Chronic Spontaneous Urticaria Skin Punch Biopsy
Chronic Spontaneous Urticaria Skin Punch Biopsy — lesional, non-lesional, or paired skin tissue from IRB-consented CSU donors. Supports dermal mast cell phenotyping, FcεRI/KIT/MRGPRX2 target validation, and endotype stratification across autoallergic and autoimmune CSU.
Chronic Spontaneous Urticaria Skin Punch Biopsy for Mast Cell and Skin Inflammation Research
Chronic Spontaneous Urticaria Skin Punch Biopsy samples are collected by licensed clinicians from IRB-consented donors with clinically confirmed chronic spontaneous urticaria (CSU). Lesional wheal tissue, non-lesional skin, or paired lesional and non-lesional punches are available in fresh or frozen formats, with punch diameter and preservation method specified to your protocol. Pricing and current availability on request.
Why Lesional Skin Matters in Chronic Spontaneous Urticaria
CSU is not an autoimmune disease of a target organ; it is a mast cell–driven skin disorder in which cutaneous mast cells degranulate inappropriately, releasing histamine and other mediators that produce transient wheals and, in many donors, angioedema. The mast cell lives in the dermis, so the cell type that defines the disease is only directly accessible in tissue.
- Mast cell biology in situ — dermal mast cell density, degranulation state, and expression of FcεRI, KIT, and MRGPRX2 can be assessed directly in lesional tissue rather than inferred from circulating surrogates
- Two recognised endotypes — type I autoallergic CSU (IgE directed against autoantigens such as thyroperoxidase) and type IIb autoimmune CSU (IgG against IgE or FcεRI); both converge on the same tissue mast cell, and tissue is where that convergence can be studied
- Target validation for approved and emerging mechanisms — anti-IgE (omalizumab), KIT-directed mast cell depletion, and BTK inhibition all act on pathways whose expression is best confirmed in skin
- Wheal histopathology — dermal oedema, vasodilation, and a sparse perivascular infiltrate of neutrophils, eosinophils, basophils, and T cells, with no epidermal change; useful for distinguishing CSU from urticarial vasculitis and other mimics
- Sensory and neuroimmune interface — mast cell proximity to cutaneous nerve fibres underlies the pruritus that dominates the patient experience
- Paired sampling — non-lesional skin from the same donor is genetically identical but phenotypically normal, isolating the lesional signal without donor-genetics confounding
Donor Stratification Available
- Disease activity — UAS7, UCT, or physician-rated activity where recorded
- Treatment response category — antihistamine-responsive, second-generation antihistamine–refractory, or on omalizumab, ciclosporin, or other systemic therapy
- Clinical phenotype — wheals only versus wheals with angioedema; disease duration
- Associated serology — total IgE, anti-thyroperoxidase, and ANA where recorded
- Sampling design — lesional wheal, non-lesional skin, or paired punches from the same donor; lesion site recorded
- Matched healthy controls available — site- and demographically matched healthy skin punch biopsies
Product Features
- Research Use Only (RUO), fresh or frozen skin punch biopsies
- Samples are frozen (if requested) within 4 hours of collection
- Clinically confirmed Chronic Spontaneous Urticaria donors
- Collected by licensed clinicians under aseptic conditions
- Punch diameter specified to protocol; FFPE, OCT, or RNA-stabilised preservation available
- Processed and shipped same-day where applicable
- IRB-approved protocols and electronic informed consent
De-identified Donor Data
- Verified diagnosis of Chronic Spontaneous Urticaria
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported medication history and lesion site
- Disease activity and clinical history available upon request
Applications
- Dermal mast cell quantification, phenotyping, and degranulation assessment
- FcεRI, KIT, and MRGPRX2 expression and target validation
- Histological and immunofluorescence analysis of wheal architecture
- Transcriptomic, proteomic, and spatial profiling across lesional and non-lesional zones
- Characterisation of eosinophil, basophil, and T cell infiltration
- Neuroimmune and pruritus mechanism studies
- Biomarker discovery and endotype stratification
- Preclinical assessment of anti-IgE, KIT-directed, and BTK-directed candidates
Other Chronic Spontaneous Urticaria Specimen Types
Matched material from the same CSU donor pool is available as chronic spontaneous urticaria serum, plasma, whole blood, and PBMC. Matched controls are available as healthy skin punch biopsy.
Compliance and Quality Assurance
- IRB-approved collections and SOP-driven processing
- 21 CFR Part 11-compliant electronic informed consent
- HIPAA-compliant donor data management
Ordering & Customization
Chronic Spontaneous Urticaria Skin Punch Biopsy samples can be shipped ambient, refrigerated, or on dry ice. For pricing, orders outside the United States, or regulatory documentation, please contact learnmore@sanguinebio.com. For the full specimen range and healthy-donor controls, see our human skin punch biopsy collection.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Skin Punch Biopsy cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.